Comparison of Prox1 expressing and Prox1 knockout intestinal tumors and the effect of A2V+CD40

Control or A2V+CD40 treated Prox1-proficient (AP) and Prox1-deficient (APP) tumors Overall design: Tumors induced in Apcflox/flox;Tp53flox/flox;villin-CreERT2 (AP) or Apcflox/flox;Tp53flox/flox;Prox1flox/flox;villin-CreERT2 (APP) mice for two weeks. Mice were randomized and treated with PBS, control IgG, or A2V+CD40 for two weeks.